Core Technology

NEWGLAB Core Technology

One of the missions of NewG Lab Pharma
(NGLP) will be to develop novel anticancer
therapeutics that extend the life of cancer patients
without compromising the quality of life.

Real World Case Study

Real World Case 1 – 16 Y/O Male
A Translational Study "Case Report" on the Small Molecule "Energy Blocker" 3-Bromopyruvate (3BP) as a Potent Anticancer Agent: From Bench Side to Bedside(2012)
The first patient to be treated with Dr. Ko's 3BP compound.

Treated at Frankfurt University in 2009

16yr old patient with progressive fibrolamellar hepatocellular carcinoma, 3 month of prognosis

The patient was given 9 doses of KAT (200 mg) over a period of 6 months

After treatment, the patient loses cancer and the tissue regenerates from 5% to 30%

1.5years after CR, the patient dies of pneumonia due to excessive antibiotic therapy
that destroyed liver function. No cancer was found as a result of CT scan by postmortem examination.

- Left images taken before treatment, right images taken after 9th treatment.

- Tumors throughout liver (L) are necrotic, encapsulated, and showing fibrosis.

- Lymph nodes that were enlarged (green star) have returned to stable size and shape.

- Spleen size (S) that was enlarged has drastically reduced.